5 results
To evaluate the efficacy, safety and tolerability of QGE031 (24 mg, 72 mg, 240 mg s.c. q4w) compared to placebo on top of SoC in atopic patients with asthma.
Primary: To characterize the QGE031 dose response relationship for the increase in the threshold dose of peanut protein that induces objective hypersensitivity reactions after treatment.Secondary (only key parameters): The percentage of patients…
D1. Comparing the made distance in meters within a fixed time between a walker and a walk-bike used by COPD patients.D2. Comparing the walking time and distance on an outdoor track between a walker and a walk-bike used by COPD patients.
Primary: To demonstrate the efficacy of QGE031 relative to placebo at 12 weeks in patients withatopic dermatitis (AD) as assessed by Eczema Area and Severity Index (EASI).Secondary: efficacy assessed by Investigator Global Assessment (IGA, 12 weeks…
To investigate the effects of exposure to low intensity monochromatic blue light compared to the effects of standard light trherapy in the treatment of SAD and winterblues